StockNews.com upgraded shares of GSK (NYSE:GSK – Free Report) from a buy rating to a strong-buy rating in a research report ...

GSK said on Friday that adding its cancer drug Jemperli to both standard-of-care chemotherapy and Zejula as a maintenance ...

On Friday, GSK plc (GSK) stock saw a decline, ending the day at $34.08 which represents a decrease of $-0.04 or -0.12% from the prior close of $34.12. The stock opened at $33.97 and touched a low of ...

GSK (NYSE:GSK – Get Free Report) was downgraded by equities researchers at StockNews.com from a “strong-buy” rating to a “buy ...

GSK (GSK) announced headline results from the FIRST-ENGOT-OV44 phase III trial evaluating Zejula and Jemperli in first line advanced ovarian cancer. The trial met its primary endpoint of PFS ...